Liver Cancer: From Molecular Mechanism to Therapeutic Perspectives
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 8202
Special Issue Editors
Interests: liver cancer; HCC; CCA; tumor ablation; tumor biopsy; immunotherapy
Interests: hepatology; liver diseases; HCC; extracellular vesicles; exosomes; microvesicles
Special Issues, Collections and Topics in MDPI journals
Interests: liver cancer; thermal ablation; minimal invasive therapies; interventional ultrasound; liver cirrhosis; pancreatistis; biliary cancers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Considering the high volume of data emerging from articles regarding liver cancer patients, we are delighted to announce our upcoming Special Issue entitled “Liver cancer: from molecular mechanisms to therapeutic perspectives”. Modern cancer medicine is shifting its perspectives from a “one drug fits all” standpoint to an individualized approach, centered on the analysis of the cellular mechanisms involved in cancer development, such as evaluating the tumor microenvironment, investigating the immune cell composition, or finding new biomarkers. These studies established new molecular targets for different drug therapies which improved overall survival in hepatocellular carcinoma or cholangiocarcinoma; however, liver cancer still remains one of the leading causes of cancer-related deaths worldwide. Undoubtedly, there is a need for a thorough understanding of the mechanisms leading to disease progression and treatment resistance, in order to decrease its global burden. This Special Issues aims to cover both preclinical and clinical studies regarding cellular signaling pathways, experimental models for liver cancer, molecular targets, diagnostic or prognostic biomarkers, and novel therapies. We are confident that our research efforts will provide novel insights into the marked heterogeneity of this type of cancer, while concurrently offer new solutions for precision treatment.
Dr. Tudor Mocan
Dr. Miroslaw Kornek
Dr. Zeno Spârchez
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- liver cancer
- HCC
- CCA
- heterogeneity
- immunotherapy
- treatment
- prognosis
- diagnosis